{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:42:20Z","timestamp":1772628140774,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T00:00:00Z","timestamp":1359072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T00:00:00Z","timestamp":1359072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>Rituximab (RTX) therapy of rheumatoid arthritis (RA) exhibits enhanced effectiveness in seropositive patients. Using patient sera, we tested if this improved efficacy was associated with enhanced RTX mediated complement-dependent cytotoxicity (RTX-CDC).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We developed an <jats:italic>in vitro<\/jats:italic> assay for RTX-CDC using patient sera and the Daudi human B cell line. Using propidium iodide uptake and flow cytometry, we compared RTX-CDC with rheumatoid factor (RF)+ sera relative to normal volunteer, non-RA and RF- sera. Additional studies examined mixing studies of RF+ and RF- sera, as well as the effect of monoclonal IgA or IgM RF. Finally, the effect of RF on RTX mediated trogocytosis of normal B cells was evaluated.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Using human sera, addition of RTX resulted in rapid and profound (&gt; 50%) Daudi cell death that was complement dependent. Surprisingly, RF+ patient sera exhibited reduced RTX-CDC relative to RF- sera, with an inverse relationship of RTX-CDC and RF titer. Mixing studies indicated the presence of an inhibitor of RTX-CDC in RF+ sera. The addition of monoclonal IgM or IgA RF to RF- sera markedly inhibited RTX-CDC. This effect was specific for RF binding to the Fc portion of RTX as it was not apparent with the F(ab)' domains of RTX engineered onto IgG3 heavy chain. RF also modestly inhibited RTX mediated trogocytosis.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Contrary to expectations, RF+ sera exhibits reduced RTX-CDC due to the presence of RF. The enhanced efficacy of RTX in seropositive RA patients cannot be attributed to improved B cell depletion through CDC. This result indicates that high RF levels may potentially modulate the efficacy of any therapeutic monoclonal antibody dependent on Fc effector function.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar4152","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T21:17:29Z","timestamp":1359148649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A rheumatoid factor paradox: inhibition of rituximab effector function"],"prefix":"10.1186","volume":"15","author":[{"given":"Jonathan D","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Shyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna M","family":"Newkirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William FC","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,25]]},"reference":[{"key":"3908_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000, 43: 155-163. 10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3.","journal-title":"Arthritis Rheum"},{"key":"3908_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/art.23149","volume":"58","author":"TM Farragher","year":"2008","unstructured":"Farragher TM, Goodson NJ, Naseem H, Silman AJ, Thomson W, Symmons D, Barton A: Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum. 2008, 58: 359-369. 10.1002\/art.23149.","journal-title":"Arthritis Rheum"},{"key":"3908_CR3","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar1861","volume":"8","author":"D Mewar","year":"2006","unstructured":"Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, Montgomery DS, Binks MH, Wilson AG: Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arth Res Therap. 2006, 8: R12-10.1186\/ar1861.","journal-title":"Arth Res Therap"},{"key":"3908_CR4","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/art.30596","volume":"63","author":"P Lal","year":"2011","unstructured":"Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ: Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum. 2011, 63: 3681-3691. 10.1002\/art.30596.","journal-title":"Arthritis Rheum"},{"key":"3908_CR5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","volume":"48","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, Cimmino M, Morassi P, Masolini P, Pellerito R, Cutolo M, Puttini PS, De Vita S: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatol. 2009, 48: 1557-1559. 10.1093\/rheumatology\/kep314.","journal-title":"Rheumatol"},{"key":"3908_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/ard.2010.148759","volume":"70","author":"K Chatzidionysiou","year":"2011","unstructured":"Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordstr\u00f6m DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF: Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011, 70: 1575-1580. 10.1136\/ard.2010.148759.","journal-title":"Ann Rheum Dis"},{"key":"3908_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1073\/pnas.89.1.94","volume":"89","author":"SE Artandi","year":"1992","unstructured":"Artandi SE, Calame KL, Morrison SL, Bonagura VR: Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc Natl Acad Sci USA. 1992, 89: 94-98. 10.1073\/pnas.89.1.94.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3908_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nsb0597-374","volume":"4","author":"AL Corper","year":"1997","unstructured":"Corper AL, Sohi MK, Bonagura VR, Steinitz M, Jefferis R, Feinstein A, Beale D, Taussig MJ, Sutton BJ: Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat Struct Biol. 1997, 4: 374-381. 10.1038\/nsb0597-374.","journal-title":"Nat Struct Biol"},{"key":"3908_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/art.1780350808","volume":"35","author":"F Stuber","year":"1992","unstructured":"Stuber F, Lee SK, Bridges SL, Koopman WJ, Schroeder HW, Gaskin F, Fu SM: A rheumatoid factor from a normal individual encoded by VH2 and V\u03baII gene segments. Arthritis Rheum. 1992, 35: 900-904. 10.1002\/art.1780350808.","journal-title":"Arthritis Rheum"},{"key":"3908_CR10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4049\/jimmunol.125.2.934","volume":"125","author":"WJ Koopman","year":"1980","unstructured":"Koopman WJ, Schrohenloher RE: In vitro synthesis of IgM rheumatoid factor by lymphocytes from healthy adults. J Immunol. 1980, 125: 934-939.","journal-title":"J Immunol"},{"key":"3908_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/art.1780360806","volume":"36","author":"X He","year":"1993","unstructured":"He X, Goronzy JJ, Weyand CM: The repertoire of rheumatoid factor-producing B cells in normal subjects and patients with rheumatoid arthritis. Arthritis Rheum. 1993, 36: 1061-1069. 10.1002\/art.1780360806.","journal-title":"Arthritis Rheum"},{"key":"3908_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1046\/j.1365-2249.2003.02198.x","volume":"133","author":"M Trendelenberg","year":"2003","unstructured":"Trendelenberg M, Schifferli JA: Cryoglobulins in chronic hepatitis C infection. Clin Exp Immunol. 2003, 133: 153-155. 10.1046\/j.1365-2249.2003.02198.x.","journal-title":"Clin Exp Immunol"},{"key":"3908_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/clim.2002.5210","volume":"104","author":"MM Newkirk","year":"2002","unstructured":"Newkirk MM: Rheumatoid factors: host resistance or autoimmunity?. Clin Immunol. 2002, 104: 1-13. 10.1006\/clim.2002.5210.","journal-title":"Clin Immunol"},{"key":"3908_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI115007","volume":"87","author":"DA Carson","year":"1991","unstructured":"Carson DA, Chen PP, Kipps TJ: New roles for rheumatoid factor. J Clin Invest. 1991, 87: 379-383. 10.1172\/JCI115007.","journal-title":"J Clin Invest"},{"key":"3908_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.1780360102","volume":"36","author":"JH Vaughan","year":"1993","unstructured":"Vaughan JH: Pathogenetic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis Rheum. 1993, 36: 1-6. 10.1002\/art.1780360102.","journal-title":"Arthritis Rheum"},{"key":"3908_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.4049\/jimmunol.178.3.1227","volume":"178","author":"R Winchester","year":"2007","unstructured":"Winchester R: A golden anniversary: recognition that rheumatoid arthritis sera contain autoantibodies specific for determinants on native IgG molecules. J Immunol. 2007, 178: 1227-1228.","journal-title":"J Immunol"},{"key":"3908_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1084\/jem.105.5.425","volume":"105","author":"EC Franklin","year":"1957","unstructured":"Franklin EC, Holman HR, Muller-Eberhard HJ, Kunkel HG: An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med. 1957, 105: 425-438. 10.1084\/jem.105.5.425.","journal-title":"J Exp Med"},{"key":"3908_CR18","first-page":"689","volume":"6","author":"RJ Winchester","year":"1970","unstructured":"Winchester RJ, Agnello V, Kunkel HG: Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis: partial characterization and relationship to lowered complement levels. Clin Exp Immunol. 1970, 6: 689-706.","journal-title":"Clin Exp Immunol"},{"key":"3908_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/art.1780180606","volume":"18","author":"H Ishikawa","year":"1975","unstructured":"Ishikawa H, Smiley JD, Ziff M: Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage. Arthritis Rheum. 1975, 18: 541-551. 10.1002\/art.1780180603.","journal-title":"Arthritis Rheum"},{"key":"3908_CR20","first-page":"501","volume":"2","author":"K Hannestad","year":"1967","unstructured":"Hannestad K, Mellbye OJ: Rheumatoid factor in synovial effusions: local production and consumption. Clin Exp Immunol. 1967, 2: 501-509.","journal-title":"Clin Exp Immunol"},{"key":"3908_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1172\/JCI108112","volume":"56","author":"HS Luthra","year":"1975","unstructured":"Luthra HS, McDuffie FC, Hunder GG, Samayoa EA: Immune complexes in sera and synovial fluids of patients with rheumatoid arthritis. Radioimmunoassay with monoclonal rheumatoid factor. J Clin Invest. 1975, 56: 458-466. 10.1172\/JCI108112.","journal-title":"J Clin Invest"},{"key":"3908_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/art.1780040105","volume":"4","author":"J Harris","year":"1961","unstructured":"Harris J, Vaughan JH: Transfusion studies in rheumatoid arthritis. Arthritis Rheum. 1961, 4: 47-55. 10.1002\/art.1780040105.","journal-title":"Arthritis Rheum"},{"key":"3908_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/art.1780250208","volume":"25","author":"UK Sabharwal","year":"1982","unstructured":"Sabharwal UK, Vaughan JH, Fong S, Bennett PH, Carson DA, Curd JG: Activation of the classical pathway of complement by rheumatoid factors: assessment by radioimmunoassay for C4. Arthritis Rheum. 1982, 25: 161-167. 10.1002\/art.1780250208.","journal-title":"Arthritis Rheum"},{"key":"3908_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/art.1780110203","volume":"11","author":"JH Vaughan","year":"1968","unstructured":"Vaughan JH, Jacox RF, Noell P: Relation of intracytoplasmic inclusions in joint fluid leukocytes to anti-IgG globulins. Arthritis Rheum. 1968, 11: 135-144. 10.1002\/art.1780110203.","journal-title":"Arthritis Rheum"},{"key":"3908_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.1780310114","volume":"31","author":"YC Ng","year":"1988","unstructured":"Ng YC, Peters K, Walport MJ: Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum. 1988, 31: 99-107. 10.1002\/art.1780310114.","journal-title":"Arthritis Rheum"},{"key":"3908_CR26","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","volume":"44","author":"MJ Glennie","year":"2007","unstructured":"Glennie MJ, French RR, Cragg MS, Taylor RP: Mechanism of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007, 44: 3823-3837. 10.1016\/j.molimm.2007.06.151.","journal-title":"Mol Immunol"},{"key":"3908_CR27","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1002\/art.34560","volume":"64","author":"JD Jones","year":"2012","unstructured":"Jones JD, Hamilton BJ, Rigby WF: Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum. 2012, 64: 3111-3118. 10.1002\/art.34560.","journal-title":"Arthritis Rheum"},{"key":"3908_CR28","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","volume":"176","author":"PV Beum","year":"2006","unstructured":"Beum PV, Kennedy AD, Williams ME, Lindofer MA, Taylor RP: The shaving reaction: rituximab\/CD20 complexes are removed from Mantle Cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol. 2006, 176: 2600-2609.","journal-title":"J Immunol"},{"key":"3908_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1084\/jem.166.2.550","volume":"166","author":"MM Newkirk","year":"1987","unstructured":"Newkirk MM, Mageed RA, Jefferis R, Chen PP, Capra JD: The complete amino acid sequences of the variable regions of two human IgM Rheumatoid Factors, BOR and KAS of the Wa idiotypic family reveals a restricted usage of heavy and light chain variable and joining region gene segments. J Exp Med. 1987, 166: 550-564. 10.1084\/jem.166.2.550.","journal-title":"J Exp Med"},{"key":"3908_CR30","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jmb.2007.02.085","volume":"368","author":"S Duquerroy","year":"2007","unstructured":"Duquerroy S, Stura EA, Bressanelli S, Fabiane SM, Vaney MC, Beale D, Hamon M, Casali P, Rey FA, Sutton BJ, Taussig MJ: Crystal structure of a human autoimmune complex between IgM rheumatoid factor RF61 and IgG1 Fc reveals a novel epitope and evidence for affinity maturation. J Mol Biol. 2007, 368: 1321-1331. 10.1016\/j.jmb.2007.02.085.","journal-title":"J Mol Biol"},{"key":"3908_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.abb.2012.02.011","volume":"526","author":"J Golay","year":"2012","unstructured":"Golay J, Introna M: Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys. 2012, 526: 146-153. 10.1016\/j.abb.2012.02.011.","journal-title":"Arch Biochem Biophys"},{"key":"3908_CR32","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.4049\/jimmunol.164.8.4178","volume":"164","author":"EE Idusogie","year":"2000","unstructured":"Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG: Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000, 164: 4178-4184.","journal-title":"J Immunol"},{"key":"3908_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60671-9","volume":"57","author":"MD Hulett","year":"1994","unstructured":"Hulett MD, Hogarth PM: Molecular basis of Fc receptor function. Adv Immunol. 1994, 57: 1-127.","journal-title":"Adv Immunol"},{"key":"3908_CR34","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.4049\/jimmunol.164.10.5313","volume":"164","author":"BD Wines","year":"2000","unstructured":"Wines BD, Powell MS, Parren PW, Barnes N, Hogarth PM: The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A. J Immunol. 2000, 164: 5313-5318.","journal-title":"J Immunol"},{"key":"3908_CR35","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/332738a0","volume":"332","author":"AR Duncan","year":"1988","unstructured":"Duncan AR, Winter G: The binding site for C1q on IgG. Nature. 1988, 332: 738-740. 10.1038\/332738a0.","journal-title":"Nature"},{"key":"3908_CR36","doi-asserted-by":"publisher","first-page":"817","DOI":"10.4049\/jimmunol.174.2.817","volume":"174","author":"Q Gong","year":"2005","unstructured":"Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y, Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F, Chan AC: Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005, 174: 817-826.","journal-title":"J Immunol"},{"key":"3908_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/eji.1830080412","volume":"8","author":"JL Van Snick","year":"1978","unstructured":"Van Snick JL, Van Roost E, Markowetz B, Cambiaso CL, Masson PL: Enhancement by IgM rheumatoid factor of in vitro ingestion by macrophages and in vivo clearance of aggregated IgG or antigen-antibody complexes. Eur J Immunol. 1978, 8: 279-285. 10.1002\/eji.1830080412.","journal-title":"Eur J Immunol"},{"key":"3908_CR38","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","volume":"344","author":"MJ Walport","year":"2001","unstructured":"Walport MJ: Complement. First of two parts. N Engl J Med. 2001, 344: 1058-1066. 10.1056\/NEJM200104053441406.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar4152\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar4152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:50:45Z","timestamp":1728384645000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar4152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,2]]}},"alternative-id":["3908"],"URL":"https:\/\/doi.org\/10.1186\/ar4152","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,25]]},"assertion":[{"value":"10 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R20"}}